Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for W-6412A (compound)

Summary
General Info

PubChem

PubChem Compound 34060

PubChem Compound 34060

Name:	Levobunolol
PubChem Compound ID:	34060
Description:	A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
Molecular formula:	C₁₇H₂₆ClNO₃
Molecular weight:	327.846 g/mol
Synonyms:	Betagan; (-)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone hydrochloride; l-Bunolol hydrochloride; 27912-14-7; Vistagan; W 7000A; 1(2H)-Naphthalenone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, hydrochloride, (-)-; EINECS 248-725-3; Levobunolol hydrochloride; Levobunolol hydrochloride [USAN]. show more » Betagan; (-)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-3,4-dihydro-1(2H)-naphthalenone hydrochloride; l-Bunolol hydrochloride; 27912-14-7; Vistagan; W 7000A; 1(2H)-Naphthalenone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-, hydrochloride, (-)-; EINECS 248-725-3; Levobunolol hydrochloride; Levobunolol hydrochloride [USAN]; 1(2H)-Naphthalenone, 3,4-dihydro-5-(3-(tert-butylamino)-2-hydroxypropoxy)-, hydrochloride, (-)-; (-)-3,4-Dihydro-5-(3-(tert-butylamino)-2-hydroxypropoxy)-1(2H)-naphthalenone hydrochloride; 1(2H)-NAPHTHALENONE, 3,4-DIHYDRO-5-(3-(tert-BUTYLAMINO)-2-HYDROXYPROPOXY)-, HYDR; (-)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-3,4-dihydronaphthalene-1(2H)-one hydrochloride; Gotensin show less «

DrugBank

Identification

Name:	Levobunolol
Name (isomeric):	DB01210
Drug Type:	small molecule
Description:	A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
Synonyms:	Levobunololum [INN-Latin]; Levobunolol HCl
Brand:	Akbeta, Betagan
Category:	Sympatholytics, Adrenergic beta-Antagonists, EENT Drugs
CAS number:	47141-42-4

Pharmacology

Indication:	For lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension.
Pharmacology:	Levobunolol is an ophthalmic beta-blocker, equally effective at β(1)- and β(2)-receptor sites. Levobunolol reduces both elevated and normal IOP in patients with or without glaucoma. In patients with elevated IOP, levobunolol reduces mean IOP by approximately 25-40% from baseline. As the drug is a nonselective &beta-adrenergic blocking age... show more » Levobunolol is an ophthalmic beta-blocker, equally effective at β(1)- and β(2)-receptor sites. Levobunolol reduces both elevated and normal IOP in patients with or without glaucoma. In patients with elevated IOP, levobunolol reduces mean IOP by approximately 25-40% from baseline. As the drug is a nonselective &beta-adrenergic blocking agent, it can produce both systemic pulmonary and cardiovascular effects following topical application to the eye. These effects include adverse pulmonary effects (eg. bronchoconstriction, increased airway resistance), and a decrease in blood pressure and heart rate. show less «
Mechanism of Action:	Levobunolol's mechanism of action in reducing IOP is not clearly defined, but is believed to be due to a reduction of the production of aqueous humor via blockage of endogenous catecholamine-stimulated increases in cyclic adenosine monophosphate (AMP) concentrations within the ciliary processes.
Absorption:	80%
Biotransformation:	Hepatic
Half Life:	20 hours
Toxicity:	Bradycardia, hypotension, bronchospasm, and acute cardiac failure, LD₅₀=700 mg/kg (orally in rat).
Affected organisms:	Humans and other mammals

Interactions

Drug interaction:

Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.

Targets

Beta-2 adrenergic receptor

Beta-1 adrenergic receptor